摘要
Purpose: Prostate cancer is the second leading cause of cancer death in men worldwide. Olaparib is clinically approved for the treatment prostate cancer, but cytotoxicity and off-target effects including DNA damage limit its clinical applications. In the current study, new strategies to improve the therapeutic efficacy of olaparib for the treatment of prostate cancer were investigated. @@@ Methods: Two prostate cancer cell lines were exposed to the c-MET inhibitor PHA665752 and/or the PARP inhibitor olaparib. Cell counting kit-8, colony formation assays, and transwell assays were conducted to evaluate the cytotoxicity of olaparib alone or in combination with PHA665752 in prostate cancer cell lines. Western blotting, immunofluorescence staining, and the comet assay were used to assess the effects of PHA665752 on olaparib-induced DNA damage. @@@ Results: Combined inhibition of c-MET and PARP resulted in effective and synergistic blocking of the growth of prostate cancer cell lines. Invasion and migration were significantly suppressed when the agents were combined. Mechanistically, dual blocking of PARP and c-MET in prostate cancer cell lines was associated with an impaired DNA damage response. Interestingly, immunofluorescence staining analysis of RAD51 protein indicated that the c-MET inhibitor PHA665752 significantly impaired homologous repair via down-regulated translocation of RAD51 into the nucleus in prostate cancer cells. @@@ Conclusion: The combination of the c-MET inhibitor PHA665752 and the PARP inhibitor olaparib may be a promising therapeutic strategy in patients with prostate cancer.
学科与关键词
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
- The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer ProliferationKuang, Qiwen; Liang, Yuxiang; Zhuo, Yangjia; Cai, Zhiduan; Jiang, Funeng; Xie, Jianjiang; Zheng, Yu; Zhong, Weide*OncoTargets and Therapy, 2021, 14: 3353-3366.被引 8
- Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancerLi, Jianhua; Wu, Huanxian; Lv, Shidong; Quan, Dongling; Yang, Danni; Xu, Jiahuan; Chen, Boyu; Ou, Baofang; Wu, Shaoyu*; Wei, Qiang*Die Pharmazie, 2022, 77(2): 59-66.被引 3
